ERBB2 and breast cancer: Targeted therapy options for HER2-positive breast cancer include Pertuzumab (Perjeta), Trastuzumab (Herceptin), Tucatinib (Tukysa), Neratinib (Nerlynx), Margetuximab (Margenza), DS-8201 (Enhertu), and Ado-trastuzumab emtansine or T-DM1 (Kadcyla)4.